Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Is it time for Design Thinking to drive R&D?

Posted on August 31st, 2016 by

Pharma R&D

digitech

According to Jon Kolko (HBR 2015), the age of “design thinking” is here. Several high tech companies appear to be taking simple design principals in moving from selling products to providing services for their users or clients. (more…)

Smart Devices, Big Data, and the Value of Long-Term Research

Posted on August 29th, 2016 by

Pharma R&D

calendar

In a new feature in The Atlantic, author Jessa Gamble makes the case that Modern Medicine Is Too Reliant on Short-Term Studies, too often preferring the instant gratification that comes from a short study, only to find those results soon challenged by yet another short-term study.

(more…)

Impact of Precision Medicine and Genomics on Patient Treatment

Posted on August 26th, 2016 by

Chemistry

DNA MAck

In January of 2015, President Barack Obama launched the Precision Medicine Initiative, which brought to the forefront the growing understanding and need for individually tailored and customized treatments for patients.

(more…)

Review of Alzheimer’s Association International Conference (AAIC16) Part 2: Focus on Secretases

Posted on August 24th, 2016 by

Pharma R&D

neurons-877576_640

In a previous blog, I provided a few thoughts on tau-related drug discovery news coming out of the recent Alzheimer’s Association International Conference (AAIC16) in Toronto, Canada. In this post, I will highlight some of the research from the conference on gamma and beta-secretase, (more…)

Elsevier and Illumina: A meeting of mind and spirit

Posted on August 22nd, 2016 by

Pharma R&D

R_D_Solutions_Blog_DNA2_DIGITAL

One of the strongest arguments for using the molecular biology modeling tool Pathway Studio is the rich content underlying its knowledge database. This was driven home recently in a conversation with the DNA/RNA sequencing company Illumina. (more…)

Compliance Metrics for Pharmacovigilance Activities

Posted on August 19th, 2016 by

Pharmacovigilance

R_D_Solutions_Blog_Compliance_DIGITAL

Measuring the compliance of a defined set of variables is key for functions like pharmacovigilance, where there is intense reporting to different regulatory and non-regulatory entities with strict regulations and high inspection risk. (more…)

  1. 1
  2. 43
  3. 44
  4. 45
  5. 46
  6. 47
  7. 62


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.